This is the latest programme, which will be updated during the following weeks.
Please note Course 1 is a one-day course and is parallel to Course 2 (half-day course) and Course 3 (half-day course).
PRE-CONFERENCE PROGRAMME
TUESDAY 20 SEPTEMBER 2022
08:30 |
09:00 |
Registration |
Polo Zanotto |
||
Pre-Conference Course 1 Advanced signal detection |
09:00–17:00 Room T3 |
||||
Signal detection is one of the main activities of Pharmacovigilance. The approach to signal generation, refinement, and confirmation has evolved over years, opening new frontiers of debate about the roles of different stakeholders in the process and the need for an implementation of regulatory frameworks, publication rules, and risk communication strategies. In 2021, the circumstances of the approval of COVID-19 vaccines were exceptional and provided an unprecedented challenge for signal detection that deserves to be studied in-depth. This one-day pre-conference course will illustrate the process of signal detection using a step-by-step approach, starting from basic elements and concluding with discussion on the most current challenges being faced. Chairs: Marco Tuccori (University of Pisa, Italy) and Ugo Moretti (University of Verona, Italy) |
|||||
09:00 |
10:00 |
Fundamentals of signal detection for drugs and vaccines Eugene Van Puijenbroek (The Netherlands Pharmacovigilance Centre Lareb, Netherlands) |
|||
10:00 |
10:30 |
Open source PV databases as sources for signal detection: strengths and limitations Ugo Moretti (University of Verona, Italy) |
|||
10:30 |
11:00 |
Publishing signal detection analysis: quality criteria Francesco Salvo (University of Bordeaux, France) |
|||
11:00 |
11:15 |
Coffee Break |
|||
11:15 |
12:00 |
State of the art in signal detection – a regulatory perspective Phil Tregunno (Medicines and Healthcare products Regulatory Agency - MHRA, UK) |
|||
12:00 |
12:45 |
Patients reporting and signal detection: strengths and limitations Linda Härmark (The Netherlands Pharmacovigilance Centre Lareb, Netherlands) |
|||
12:45 |
14:00 |
Lunch break |
|||
14:00 |
14:45 |
Causality and chance in recent pharmacovigilance signals of COVID-19 vaccines: what evidence for public health decisions? Bernard Bégaud (University of Bordeaux, France and chair of the EPIPHARE scientific committee) |
|||
14:45 |
15:30 |
Signal detection using Pharma industry databases Maria Maddalena Lino (Pfizer, Italy) |
|||
15:30 |
15:45 |
Coffee break |
|||
15:45 |
16:15 |
Signal detection for oncologic drugs Emanuel Raschi (University of Bologna, Italy) |
|||
16:15 |
17:00 |
Managing signal detection during crisis in Regulatory Agencies and Pharmacovigilance Regional Centers Pasquale Marchione (Agenzia Italiana del Farmaco (AIFA), Italy) |
|||
19:30 |
21:00 |
Welcome Reception – University of Verona, Cloister of San Francesco |
|||
Pre-Conference Course 2 Introduction to pharmacoepidemiology studies and their role in Pharmacovigilance 09:00–12:45 |
09:00–12:45 Room T2 |
||||
The aim of this half-day course is to provide a basic understanding of the concepts and practice of pharmacoepidemiology. You will learn about the fundamentals of pharmacoepidemiology, its practical uses and its limitations, as well as how pharmacoepidemiology and pharmacovigilance can be used together to inform medicines safety. By the end of the course, participants should be able to: • demonstrate an understanding of basic study designs commonly used in pharmacoepidemiology • gain an understanding of fundamental statistical concepts • be familiar with potential sources of error and the limitations of pharmacoepidemiological studies • understand how data from pharmacovigilance and pharmacoepidemiology can be synthesized into evidence of safety Chair: Rebecca Chandler (ISoP Vice-President, Coalition for Epidemic Preparedness Innovations, Sweden) Co-Chairs:Gianmario Candore (Bayer, Germany) and Houda Sefiani (Moroccan Pharmacovigilance Centre, Rabat WHO Collaborating Centre, Morocco) |
|||||
09:00 |
09:10 |
Welcome and Introduction |
|||
09:10 |
09:40 |
Overview of study designs in pharmacoepidemiology Ylenia Ingrasciotta (University of Verona, Italy) |
|||
09:40 |
10:10 |
Essential statistics for pharmacoepidemiology Edward Burn (University of Oxford, UK) |
|||
10:10 |
10:30 |
Q&A |
|||
10:30 |
10:45 |
Coffee break |
|||
10:45 |
11:15 |
Sources of error in pharmacoepidemiology Ersilia Lucenteforte (University of Pisa, Italy) |
|||
11:15 |
11:45 |
Overview of large health care databases Edward Burn (University of Oxford, UK) |
|||
11:45 |
12:15 |
Pharmacoepidemiology and its role within pharmacovigilance Samantha Lane, Drug Safety Research Unit (DSRU), UK |
|||
12:15 |
12:45 |
Q&A |
|||
13:00 |
14:00 |
Lunch / End of Course 2 |
|||
Pre-Conference Course 3 Regulatory Updates across the Continuum of Spontaneous Reporting to Risk Minimization |
13:30–17:00 Room T2 |
||||
This half-day course will address regulatory challenges and ‘state-of-the-art’ methodological approaches to current issues across the continuum of spontaneous reporting to risk minimization. With a multi-region focus, learn about how the QPPV role has evolved to deal with increasingly complex pharmacovigilance regulations; hear from EMA speakers about the EU’s novel analytical methodologies in signal detection and risk assessment and methods for effectiveness evaluation of risk minimisation measures (RMMs); and learn about how Morocco is prioritizing multi-stakeholder involvement in risk management planning and implementation on a local level. There will be plenty of time for Q&A and we look forward to lively discussion. Chairs: Deirdre McCarthy (ISoP Executive member, Gates MRI, USA) and Giampiero Mazzaglia (Milano Bicocca university, Italy) |
|||||
13:30 |
14:10 |
QPPV Role: Insight and trends Barbara De Bernardi (Pfizer, Italy) |
|||
14:10 |
14:50 |
Novel analytical methodologies in signal management and risk assessment Cosimo Zaccaria (European Medicines Agency - EMA, Netherlands) (Virtual presentation) |
|||
14:50 |
15:10 |
Coffee break |
|||
15:10 |
15:50 |
Methods for effectiveness evaluation of risk minimisation measures (RMMs) Tomas Goedecke (European Medicines Agency - EMA, Netherlands) (Virtual presentation) |
|||
15:50 |
16:30 |
Importance of multi-stakeholder involvement in risk management planning and implementation Ghita Benabdallah (Centre Anti Poison et de Pharmacovigilance du Maroc (CAPM), Morocco) |
|||
16:30 |
17:00 |
Panel discussion and wrap-up |
|||
19:30 |
21:00 |
Welcome Reception – University of Verona, Cloister of San Francesco |
Pre-conference courses are not part of the registration fee. Please see the fees and registration guidelines here